prostate cancer

Johnson & Johnson's Prostate Cancer Pill Just Posted a 75% Response Rate — Why JNJ Is Monday's Stock to Watch

2026-10-25

Johnson & Johnson (NYSE: JNJ) announced on Sunday, October 25, 2026, that its experimental once-daily prostate cancer pill JNJ-6143 produced a confirmed complete or partial tumor response in 75% of...